Cite
HARVARD Citation
Gulley, J. et al. (n.d.). 3090 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or recurrent non-small-cell lung cancer progressing after platinum-based chemotherapy: A phase Ib trial. European journal of cancer. pp. S629-. [Online].